NCT00868907View on ClinicalTrials.gov

Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Healthy
Interventions
DRUG

35 mg risedronate DR tablet

35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet

DRUG

35 mg risedronate DR tablet

35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner

DRUG

35 mg risedronate DR tablet

35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast

Trial Locations (4)

32601

Research Site, Gainesville

33126

Research Site, Miami

47711

Research Site, Evansville

96821

Research Site, Honolulu

Sponsors

Lead Sponsor

Warner Chilcott

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Warner Chilcott

INDUSTRY

NCT00868907 - Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food | Biotech Hunter | Biotech Hunter